Teplizumab (also known as PRV-031) is a humanized antibody medication that targets a protein called CD3 on immune cells. It is designed to help people with recently diagnosed Type 1 diabetes by modifying the immune system’s response. The medication works by attempting to preserve the body’s ability to produce insulin by preventing the immune system from attacking insulin-producing cells in the pancreas. This treatment is being studied specifically in children and adolescents who have been recently diagnosed with Type 1 diabetes.

Type 1 Diabetes Mellitus – A chronic condition where the body’s immune system attacks and destroys insulin-producing cells in the pancreas. This results in little to no insulin production, preventing cells from properly using glucose from food for energy. The condition typically develops during childhood or adolescence, though it can occur at any age. People with this condition experience high blood sugar levels and need to carefully monitor their glucose. The body’s inability to produce insulin leads to various metabolic changes and requires regular blood sugar management. Without proper insulin, the body begins to break down fat and muscle for energy, leading to various metabolic changes.